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Anaphylatoxin formation during hemodialysis: Effects of different
dialyzer membranes. Measurable complement activation resulting in the
formation of both C3a and C5a anaphylatoxins was observed in 12
patients undergoing maintenance dialysis treatment with cuprophan
hollow fiber dialyzers. Specific radioimmunoassay measurements dem-
onstrated that these patients displayed significantly elevated levels of
C3a antigen in the venous (outflow) line of the dialyzer after only 2 mm
of dialysis. During hemodialysis, venous plasma C3a levels continued
to increase and became maximally elevated after 15 mm. Thereafter,
C3a concentrations gradually declined, suggesting that the rate of
complement activation abates with continued cuprophan hemodialysis.
Complement activation, as judged by venous plasma C3a levels, was
also temporally correlated with hemodialysis leukopenia. The factor
believed to be responsible for pulmonary vascular leukosequestration,
C5a, could also be detected in venous plasma, but levels of this antigen
were not strikingly elevated until the later stages of dialysis. By
contrast, six patients dialyzed with polyacrylonitrile dialyzers failed to
exhibit hemodialysis leukopenia and displayed only very modest in-
creases in their plasma C3a levels during the initial phases of hemodial-
ysis. These observations provide direct evidence that anaphylatoxin
formation during hemodialysis is a transient phenomenon and indicate
that the biocompatibility of dialysis membranes, as reflected by their
complement activating potential, may be significantly different.
Formation d'anaphylatoxines pendant l'hémodialyse: Effets de differ-
entes membranes de dialyseurs. Une activation mesurable du comple-
ment, aboutissant a Ia formation d'anaphylatoxines C3a et C5a été
observCe chez 12 malades en hémodialyse periodique avec des dialy-
seurs a fibres capillaires en cuprophan. Des mesures radioimmunologi-
ques spécifiques ont démontré que ces malades avaient des niveaux
significativement élevés d'antigenes C3a dans Ia ligne veineuse (sortie)
du dialyseur aprCs 2 mm seulement de dialyse. Pendant l'hémodialyse,
les concentrations plasmatiques veineuses de C3a ont continu. a
augmenter, et sont devenues maximales après 15 mm. Ensuite, les
concentrations de C3a ont diminuC progressivement, suggerant que Ia
vitesse de l'activation du complement diminue pendant Ia poursuite de
l'hémodialyse au cuprophan. L'activation du complement, jugee par les
concentrations plasmatiques veineuses de C3a, était Cgalement
reliée dans Ic temps avec Ia leucopénie de l'hemodialyse. Le facteur
suppose être responsable de Ia leucosequestration vasculaire plumon-
aire, le C5a, était egalement detectable dans Ic plama veineux, mais les
niveaux de cet antigene n'étaient pas élevés de facon marquee avant les
stades tardifs de Ia dialyse. A l'inverse, six malades dialyses avec des
dialyseurs en polyacrylonitrile n'ont pas eu de leucopCnie de l'hémodia-
lyse, et n'ont montre que des augmentations tres modestes de leur
niveau plasmatique de C3a pendant les phases initiales de l'hemodia-
lyse. Ces observations apportent une preuve directe que Ia formation
d'anaphylatoxmnes pendant l'hémodialyse est un phénomene transitoire
et indiquent que Ia biocompatibilite des membranes de dialyse, reflétee
par leur potentiel d'activation du complement, pourrait étre signifiica-
tivement diffCrente.
Chronic maintenance dialysis is commonly practiced. In the
United States alone, an estimated 200 uremic patients per
million population undergo this procedure each year [I]. In the
vast majority of cases, these patients are dialyzed with devices
containing primarily cellulosic membranes. One form of cellu-
losic membrane, cuprophan, is used most widely for these
procedures.
Numerous investigators have noted that transient granulocy-
topenia, which results from reversible pulmonary vascular
leukosequestration, is usually manifest by patients during the
initial phases of hemodialysis with cellulosic membranes [2—6].
This phenomenon most likely results from activation of granu-
locytes by a complement-derived fragment that is chemically
and biologically similar to, if not identical with, C5a or its des
Arg derivative [7, 81. Human C5a is in turn thought to be
produced as a consequence of membrane-induced activation of
the complement system through alternative pathway mecha-
nisms [7, 9, 10]. This series of events reportedly can produce
varying degrees of pulmonary dysfunction and possibly contrib-
ute to hypoxemia in the dialyzed patient [11, 12].
Noncellulosic membrane formulations have also been utilized
in artificial kidney devices and certain of these polymers,
including polyacrylonitrile, polycarbonate, and polyelectrolyte
membranes, have been reported to be more compatible with
blood than the cellulosic membrane [5, 6, 13]. One explanation
for these apparent differences is that noncellulosic membranes
activate complement poorly when compared to cellulosic ones.
To test this hypothesis, sensitive radioimmunoassay tech-
niques that quantitatively determine the plasma concentrations
of the complement-derived C3a, C4a, and C5a antigens were
used to define and compare the complement activating capabili-
ty of cuprophan and polyacrylonitrile membranes.
Methods
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Patients. Eighteen male patients, ranging in age from 50 to 65
years, who were free of intercurrent disease and had been
stable on chronic maintenance dialysis for at least 1 year (mean
duration, 5 years) voluntarily participated in this study. Twelve
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Table 1. Comparison of plasma C3a and C5a antigen levels in normal, uremic, and chronically dialyzed individuals
Group N
Plasma anaphylatoxin concentration, ng/ml
C3a C5a
Range Mean SEM Range Mean SEM
Normal controls
Nondialyzed uremic patients
Chronically dialyzed patients
Cuprophan membrane
PAN membrane
24
8
18
12
6
0 to 233
36 to 618
115 to 867
115 to 867
131 to 423
76
316
364
401
291
15
66°
45°
61°
45°
0 to 75
17 to 85
0 to 118
0 to 118
0 to 86
14 4
60 9°
55 9°
67 Ila
31 15
a Plasma concentration of anaphylatoxin antigen was significantly elevated compared to normal controls (P < 0.001).
patients were being routinely dialyzed with cuprophan hollow
fiber dialyzers (CF- 1211 or CF- 1511, Travenol Laboratories,
Deerfield, Illinois, or GF-120H, Gambro AB. Wheeling, Illi-
nois). The remaining six patients were dialyzed routinely with
polyacrylonitrile sheet membrane devices (Hospal RP-6, East
Brunswick, New Jersey). Patients treated with the RP-6 mem-
brane, in conjunction with an ultrafiltration controller unit
(Cotral, Hospal), had been dialyzed in this manner for several
months prior to this study because they each consistently
exhibited a high incidence of symptomatic hypotension during
routine dialysis treatment that employed cellulosic membranes
and dialyzer equipment with less rigorous fluid balance moni-
toring. None of these patients received either corticosteroids or
nonsteroidal anti-inflammatory agents. This study protocol was
approved by the Human Subjects Committee of the University
of California, San Diego, and informed consent was obtained
from each participant.
Dialysis procedures. Drake-Willock machines were used to
cycle dialysate at a flow rate of 500 mI/mm in the single pass
mode. Dialysate temperature was maintained at 34 to 38°C.
Additionally, when the PR-6 membranes were used, the ultrafil-
tration controller unit was used to insure smooth fluid removal
with this highly water permeable membrane. During dialysis,
blood flow was maintained at a rate of 205 to 232 mI/mm.
Sampling procedures. Whole blood samples were drawn
from the patient's arteriovenous fistula after heparinization, but
prior to dialysis (time 0), and 10 mm after completion of dialysis
(post). During the 4-hr dialysis procedure, blood samples were
obtained simultaneously from both the arterial (patient to
dialyzer) and venous (dialyzer to patient) lines of the dialyzer
at: 2, 5, 10, 15, 30, and 60 mm and at 60-mm intervals thereafter.
All blood samples were immediately anticoagulated with disodi-
um ethylenediamine tetra-acetate (EDTA, final concentration,
20 mM) to prevent further complement activation.
Assay procedures. EDTA-anticoagulated blood samples were
analyzed immediately after completion of the dialysis proce-
dure. Total white blood cell (WBC) counts were first obtained
with a cell counter (Coulter Model ZF, Coulter Electronics,
Hialeah, Florida). Then, EDTA-anticoagulated plasma was
obtained by centrifugation at x2000g for 15 mm. The plasma
concentrations of C3a, C4a, and C5a antigens were determined
by radioimmunoassay (RIA) procedures previously described
in detail l4, 15], As noted previously, the antisera used in these
RIA procedures permit detection of either the intact anaphyla-
toxin molecules or their des Arg derivatives with equal facility.
Statistical comparisons reported in Table 1 were made with
Student's unpaired t test. All other comparisons were made
with a paired t test. Statistically significant differences were
defined by a P value of less than or equal to 0.05.
Results
Normal plasma anaphylatoxin levels. Normally, trace quan-
tities of both C3a and C5a antigens, which probably occur as the
C3ades Arg and CSade. Arg form of the anaphylatoxins, are
observed in EDTA-anticoagulated plasma (Table I). By con-
trast, most uremic patients, whether being dialyzed or not,
typically displayed elevated plasma levels of C3a and C5a
antigens (Table 1). Uremic patients who were not being dia-
lyzed had elevated plasma concentrations of both C3a and C5a
antigens that were comparable to those detected in the predialy-
sis plasma of hemodialyzed patients. Interestingly, patients
routinely treated with polyacrylonitrile (PAN) dialysis mem-
branes tended to have lower predialysis levels of both C3a and
C5a antigens than their cuprophan dialyzed counterparts, al-
though these differences were not statistically significant.
Cuprophan membrane hemodialysis. The occurrence of tran-
sient leukopenia in patients during dialysis with cuprophan
hollow fiber dialyzers was confirmed by determining total white
blood cell (WBC) counts in 12 patients prior to hemodialysis
and at various times during the procedure. As shown in Figure
I, the total number of white blood cells in both arterial and
venous blood samples began to decrease immediately after the
institution of hernodialysis and continued to decline as a func-
tion of time for the first 15 mm of treatment. Ten of the 12
patients studied exhibited maximal leukopenia after 10 or 15
mm of dialysis and the other two after 30 mm. Following this
nadir, both arterial and venous blood leukocytes gradually
increased in number, returning to predialysis levels within an
hour after the onset of dialysis.
Comparison of arterial and venous blood WBC counts dem-
onstrated that, in the first 2 mm of hemodialysis, venous WBC
counts were less than those of the arterial blood, suggesting that
the initial events of cuprophan hemodialysis might include a
brief sequestration of leukocytes within the dialyzer itself. By
contrast, after 5, 10, and 15 mm of dialysis, arterial blood WBC
counts were less than those of venous blood, an observation
that is consistent with leukosequestration in the dialyzed
patient.
Radioimmunoassay quantitation of C3a antigen in both arteri-
al and venous blood samples not only confirmed that comple-
ment activation was associated with cuprophan hemodialysis,
but also demonstrated that complement activation, like hemodi-
alysis leukopenia, is largely a transient phenomenon. Sequen-
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Time on hemoclialysis, mm
Fig. 1. Relative leukocyte counts in the arterial (open circles) and
venous (closed circles) blood of patients during hemodia/ysis with
cuprophan or polyacrylonitrile dialyzers. Each data point represents
the mean of duplicate determinations in 12 separate dialysis procedures
with cuprophan or six separate procedures with polyacrylonitrile.
tial measurements of the plasma levels of C3a antigen (presum-
ably C3ades Arg) demonstrated the immediate appearance of
significant quantities (P < 0.01) of this C3-derived polypeptide
in venous blood (Fig. 2). Accumulation of C3a antigen in blood
flowing from the dialyzer to the patient continued briskly for the
first 5 mm of dialysis and at a somewhat slower rate for the next
10 mm. After 15 mm of hemodialysis, venous plasma C3a levels
were maximally elevated, being more than 15-fold greater than
predialysis levels (P < 0.001). All 12 patients exhibited this
temporal profile, with maximal levels of C3a antigen observed
in venous plasma after only 10 or 15 mm of dialysis. Continued
hemodialysis was associated with a gradual decline in the
venous plasma concentration of C3a antigen. However, even 10
mm after completion of the 4-hr procedure, plasma C3a antigen
levels continued to be significantly elevated when compared to
predialysis values (mean SEM, post = 561 40 ng/ml vs. pre
= 401 61 ng/ml, P < 0.05).
The amount of C3a antigen detected in arterial blood samples
paralleled that observed in venous blood. Arterial blood C3a
antigen levels rose significantly (P < 0.05) within 5 mm after
beginning hemodialysis and were maximally elevated 30 mm
after the onset of the procedure. However, the absolute amount
of C3a antigen present in blood flowing from the patient to the
dialyzer was always significantly less than that observed emerg-
ing from the dialyzer itself.
Comparison of the data in Figures I and 2 suggested that the
transient leukopenia of hemodialysis might be temporally asso-
ciated with complement activation, as judged by C3a antigen
formation. Linear regression analysis supported this hypothe-
sis. Comparison of the relative arterial WBC counts (y) with the
corresponding venous C3a antigen concentration (x) at each
time point during the first hour of hemodialysis demonstrated a
highly significant relationship defined by the equation y =
—0.Olx + 109.1 (r = 0.894, P < 0.001). This close correlation
between elevated plasma C3a antigen levels and diminished
leukocyte counts supports the concept that complement activa-
Time on hemodialysis, mm
Fig. 2. Plasma levels of C3a antigen during hemodialysis with cupro-
phan orpolyacrylonitrile dialyzers. Mean (± SEM) concentrations of the
polypeptide in both arterial (open circles) and venous (closed circles)
blood of 12 patients dialyzed with cuprophan are shown. Mean (± SEM)
venous plasma levels of C3a antigen observed in six patients dialyzed
with polyacrylonitrile dialyzers (closed circles) are also shown.
tion may promote pulmonary vascular leukosequestration. It
should be emphasized that we do not wish to propose that C3a,
C3ades Arg or any antigenically related polypeptides acts directly
to promote leukocyte activation. As will be discussed, the
observation that C3a antigen is readily detected in plasma,
rather than being bound to the cellular elements of blood, not
only implies that C3a is probably not responsible for granulo-
cyte activation in vivo but also supports the concept that RIA
measurements of C3a antigen levels provide a more accurate
assessment of complement activation than similar measure-
ments of plasma C5a antigen concentrations.
Human C5a anaphylatoxin, and/or its des Arg derivative, is
generally considered to be the agent responsible for promoting
hemodialysis leukopenia [7, 8]. Radioimmunoassay quantita-
tion of C5a antigen in both arterial and venous blood samples
obtained from cuprophan hemodialyzed patients demonstrated
only a modest elevation of the plasma levels of this antigen
during the first 2 hr of hemodialysis (Fig. 3). Although the
venous concentrations of this granulocyte activating factor
were significantly elevated (P < 0.05) after 15 mm, the most
dramatic increase in plasma levels occurred only after 3 hr of
treatment. Arterial blood samples did not contain significantly
increased quantities of C5a antigen at any time during hemodial-
ysis. Shortly after completion of the hemodialysis procedure,
plasma C5a levels decreased and were not elevated significantly
when compared to predialysis levels (mean SEM, post 100
25 ng/mI vs. pre = 67 II ng/ml).
Both arterial and venous plasma levels of C4a antigen were
also determined by RIA procedures. No significant changes in
the concentration of this polypeptide antigen, which results
from complement activation by classical pathway mechanisms,
were observed in either the efferent or afferent lines of the
cuprophan dialyzer at any time during the procedure (data not
shown).
Polyacrylonitrile membrane hemodialysis. Six patients were
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Fig. 3. Plasma levels of C5a antigen during cuprophan orpolyacryloni-
true hemodialysis. Mean (± 5EM) concentrations of the glycopolypep-
tide in both arterial (open circles) and venous (closed circles) blood of
12 cuprophan dialyzed patients are shown. Mean (± 5EM) venous
plasma levels of C5a antigen detected in six patients during polyacry-
lonitrile hemodialysis (closed circles) are also shown.
treated with a hemodialysis procedure employing a polyacry-
lonitrile sheet membrane. In marked contrast to the cuprophan
hemodialyzed patients, this group did not display a typical
pattern of hemodialysis leukopenia with a nadir after 15 mm.
Instead, as shown in Figure 1, these individuals demonstrated a
transient sequestration of leukocytes within the dialyzer itself
during the first 2 mm of dialysis, as manifest by the fact that the
venous blood WBC counts fell significantly when compared to
either predialysis (P < 0.01) or the 2-mm arterial (P 0.05)
blood samples. Apart from this brief episode of mild dialyzer-
associated leukopenia, WBC counts in both arterial and venous
blood did not differ significantly from predialysis counts
throughout the course of hemodialysis with the polyacryloni-
trile membrane. In fact, after 30 mm of dialysis with this
membrane, WBC counts were slightly elevated and remained so
for the duration of the procedure.
As shown in Figure 2, polyacrylonitrile membrane promoted
markedly less C3a antigen formation than cuprophan mem-
brane. Patients dialyzed with polyacrylonitrile membrane dia-
lyzers displayed a modest but significant increase (P < 0.05) in
their venous C3a antigen levels after 5 mm of treatment. Even
so, the absolute quantity of C3a antigen present in the efferent
lines of these dialyzers was less than one-tenth that observed
with cuprophan dialyzers. After 5 mm of dialysis with polyacry-
lonitrile membrane, venous C3a antigen concentrations rapidly
returned toward pretreatment levels. Arterial levels of C3a
antigen were not increased significantly at any time during
dialysis with this membrane. Additionally, RIA quantitation
failed to demonstrate a significant increase in either the venous
(Fig. 3) or arterial (data not shown) levels of C5a antigen or C4a
antigen (data not shown) at any time during dialysis with
polyacrylonitrile membrane.
Discussion
Human C3a anaphylatoxin is cleaved from the amino termi-
nus of the a-chain of C3 when complement is activated by either
classical or alternative pathway mechanisms. Once liberated
into the fluid phase, C3a is rapidly converted to its des Arg
derivative (C3ades Arg) by the action of a serum carboxypepti-
dase. Both C3a and C3ad Arg may be specifically detected with
equal facility by our current radioimmunoassay methods [14,
15]. Our observation that plasma levels of C3a antigen are
elevated markedly during the initial phases of hemodialysis
confirms that significant complement activation and anaphyla-
toxin formation takes place in extracorporeal circuits contain-
ing cuprophan hollow fiber membranes. Furthermore, these
quantitative studies clearly demonstrate that anaphylatoxin
formation, like hemodialysis granulocytopenia, is a transient
phenomenon taking place predominantly in the first 30 mm of
hemodialysis. By contrast, hemodialyzers containing polyacry-
lonitrile membrane promote very little complement activation
and correspondingly fail to induce hemodialysis leukopenia.
During the past 5 years, Craddock et al [7, 11] and other
investigators [2—5] have used both bioassays and classical
immunological techniques to demonstrate convincingly that the
transient leukopenia of hemodialysis results from a series of
events which may be briefly summarized as follows. Contact of
the patient's blood with cellulosic membrane promotes comple-
ment activation, predominantly through alternative pathway
mechanisms. As a result, C5a anaphylatoxin and/or its des Arg
derivative is released into the fluid phase. This glycopolypep-
tide, which binds avidly to plasma membrane receptors found
on both neutrophils and monocytes [16, 17], promotes granulo-
cyte aggregation as well as increased adherence of these cells.
Whether embolization of granulocyte aggregates or direct ad-
herence of these cells to the endothelium predominates, the net
effect of CSa-mediated granulocyte activation is to produce
pulmonary vascular leukosequestration which is manifest as a
peripheral leukopenia in the cuprophan dialyzed patient. By
contrast, polyacrylonitrile membranes reportedly induce very
little hemodialysis leukopenia [6, 13], a fact that correlates well
with our observation that these membranes activate very little
complement.
The fact that hemodialysis leukopenia is a transient phenome-
non has been ascribed to two different mechanisms. Initially, it
was postulated that the cellulosic membrane displayed a pro-
gressive inability to activate complement during the course of
the dialysis procedure [7]. More recently, these same investiga-
tors have suggested that selective granulocyte deactivation
toward C5a might account for the transience of the leukostasis
routinely observed in these patients [18]. Our own investiga-
tions suggest that both of these explanations may be valid.
First, RIA measurements of plasma C3a antigen levels clearly
demonstrate that complement activation occurs predominantly
in the first 30 mm of hemodialysis with cuprophan hollow fiber
membranes. The activation process begins as soon as blood
contacts the dialyzer membrane surface and continues vigor-
ously for the first 5 mm of treatment. During the next 10 mm,
C3a antigen continues to be produced, but at a somewhat
slower rate. After 30 mm of dialysis, C3a antigen continues to
appear in the efferent (venous) line of the dialyzer, but its
concentration is gradually reduced, indicating a continuously
declining rate of formation within the dialyzer itself. The
observation that peripheral blood WBC counts are inversely
proportional to the efferent plasma concentrations of C3a
antigen during the first hour of hemodialysis not only implies
0 15 30 60 120 180 240 Post
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that complement activation promotes leukopenia in the early
phases of dialysis but also suggests that the reversal of this
phenomenon may also be dependent on cessation of these
activation processes. Additionally, our finding that exposure of
granulocytes to C5a for 30 mm at 37°C promotes 'down
regulation" of the C5a receptor and subsequent cellular unre-
sponsiveness to this factor [15] agrees with Skubitz and Crad-
dock's hypothesis [18] that deactivated granulocytes may be
released from the pulmonary microvasculature and subsequent-
iy reappear in circulation at precisely the same time that the
tempo of complement activation in the dialyzer abates.
Other investigators have employed indirect methods to dem-
onstrate that activated complement components may be readily
detected in efferent (venous) dialyzer lines but not in afferent
(arterial) ones [18]. RIA quantitation methods possess sufficient
sensitivity to demonstrate that the plasma concentration of C3a
antigen in the blood circulating from the patient to the dialyzer
(arterial line) actually becomes significantly elevated within 5
mm after initiation of dialysis. The fact that arterial plasma C3a
antigen levels never exceed those seen in the venous return
from the dialyzer indicates that clearance of the low molecular
weight cationic polypeptide takes place at undefined sites
within the patient during hemodialysis. However, as noted in
Table I, these same dialysis patients usually have elevated
levels of plasma C3a antigen prior to dialysis, suggesting that
their ability to metabolize and excrete this factor normally is
impaired and/or they display enhanced complement activation
as a result of their underlying disease process. The observation
that uremic nondialyzed patients have similarly elevated plasma
C3a antigen levels suggests that the C3a antigen present in the
circulation of dialyzed patients between treatments cannot be
ascribed solely to accummulation of this factor as a conse-
quence of chronic dialysis.
As we reported previously [19], RIA quantitation of C3a
antigen provides a considerably more sensitive indication of
complement activation than does measurement of plasma C5a
antigen levels. Again, we observe that, even though C3a antigen
levels rise over 15-fold during hemodialysis and attain plasma
concentrations equivalent to the conversion of approximately
10% of the available plasma C3, CSa antigen levels do not
increase strikingly until near the end of the dialysis procedure.
These observations are compatible with the fact that very little
C3a is bound to the formed elements of blood. By contrast, C5a
is not only bound to peripheral blood granulocytes [16, 17] but
is also rapidly metabolized and cleared from circulation. Stud-
ies conducted with rabbits indicate that the intravascular half-
lives of '251-C5a and '251-C5ades Aug are only I and 2 mm,
respectively [20]. Furthermore, both the CSa-activated granulo-
cyte itself, which internalizes and degrades this ligand [21—231
and other organs, especially the liver, are primarily responsible
for the rapid disappearance of this factor from circulation [20].
Correspondingly, our RIA measurements indicate only a mod-
est elevation of plasma C5a antigen levels during the early
phase of hemodialysis. Detection of strikingly elevated levels of
C5a antigen during the later phases of cuprophan hemodialysis
suggests that ligand binding sites on both granulocytes and
other tissues may eventually become saturated.
Patients dialyzed with polyacrylonitrile membranes provide a
most interesting contrast to those dialyzed with cellulosic ones.
During the first 5 mm of dialysis with polyacrylonitrile devices,
the venous plasma levels of C3a antigen double and then rapidly
decline toward predialysis levels. Venous plasma concentra-
tions of C5a antigen do not become significantly elevated at any
time during these dialysis procedures. These findings suggest
that polyacrylonitrile may activate complement, but the com-
plement activating potential of this biopolymer is minimal since
both the duration and the magnitude of these activation events
are considerably less than those observed when cuprophan is
used. As a consequence, hemodialysis leukopenia is not a
prominent feature when PAN dialyzers are used in the extracor-
poreal circuit. We believe that these observations accurately
reflect the limited complement activating capacity of polyacry-
lonitrile membranes rather than indicate an inability of these
particular patients to activate complement because each of
these six patients exhibited hemodialysis leukopenia as well as
other systemic symptoms when dialyzed with cuprophan type
dialyzers.
Our clinical findings are compatible with recent biochemical
investigations that have delineated the initial events regulating
activation of the alternative pathway of complement [24, 25].
According to current concepts, C3 contains a highly reactive
internal thiolester bond at its active site and hydrolysis of this
bond continuously provides a source of trace amounts of a
functionally C3b-like molecule in human plasma [26]. This
altered form of C3, in the presence of factors B and D and
Mg+ +, is capable of forming a C3 convertase that can generate
metastable C3b by proteolytic cleavage of native C3. Activation
of the alternative pathway of complement begins when this
highly labile form of C3b attaches to an appropriate activating
surface through a covalent bond formed by transesterification
of the active site thiolester group. Once initiated in this fashion,
positive regulatory factors of the alternative pathway insure
that complement activation proceeds rapidly until available C3b
binding sites become saturated [26]. When these activating sites
have become fully occupied, negative regulatory factors come
into play and gradually reduce the amount of C3 conversion
taking place [26].
In light of these constructs, we speculate that exposure of the
dialyzed patient's blood to either cuprophan or polyacryloni-
true membranes promotes rapid complement activation through
alternative pathway mechanisms, as evidenced by the fact that
no conversion of C4 is observed at any time during dialysis.
Conversion of C3 and resultant C3a formation takes place on
both cuprophan and polyacrylonitrile surfaces at comparable
rates during the first 5 mm of dialysis, presumably as C3b
molecules become attached to available binding sites. Howev-
er, when polyacrylonitrile dialyzers are utilized, C3b deposition
abruptly terminates after 5 mm because this membrane has a
limited capacity to covalently bind C3b. By contrast, we feel
that complement activation on the cuprophan membrane is
markedly greater than that observed with polyacrylonitrile
because cuprophan either possesses a relatively large number
of C3b binding sites or the chemical nature of these sites
renders them highly reactive with C3b. Cessation of C3a
antigen formation in either PAN or cuprophan dialyzers, after 5
or 15 mm, respectively, suggests that the transient nature of
complement activation results from saturation of these C3b
binding sites.
The observations reported here not only define the temporal
profile and magnitude of anaphylatoxin formation promoted by
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different hemodialysis membranes, but they may be of general
interest for the following reasons. If additional experimentation
confirms that complement activation on these membrane sur-
faces actually proceeds by the mechanisms envisioned, we
would also predict that it should be possible to chemically
modify the nucleophilic groups of biopolymers such as cupro-
phan and thus effectively eliminate their complement-activating
potential, Additionally, application of C3a RIA techniques
provide a reliable quantitative means of defining the comple-
ment-activating potential of the varied biopolymers that are
utilized in extracorporeal devices. Because C3a RIA kits are
now commercially available (Upjohn Diagnostics, Kalamazoo,
Michigan), studies directed toward identifying biocompatible
membranes with little if any complement-activating capacity
may be readily conducted by investigators interested in these
concepts. To the degree that complement activation and ana-
phylatoxin formation are indeed responsible for some of the
undesirable clinical sequellae associated with hemodialysis or
even other extracorporeal procedures, such a cardiopulmonary
bypass [19], investigations along these lines seem warranted.
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